The Role of Angiogenesis in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is the second leading cause of cancer-related deaths worldwide. The hypervascular nature of most HCC tumors underlines the importance of angiogenesis in the pathobiology of these tumors. Several angiogenic pathway...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 25; no. 3; p. 912
Main Authors:	Morse, Michael A, Sun, Weijing, Kim, Richard, He, Aiwu Ruth, Abada, Paolo B, Mynderse, Michelle, Finn, Richard S
Format:	Journal Article
Language:	English
Published:	United States 01.02.2019
Subjects:	Angiogenesis Inhibitors - therapeutic use Angiostatins - therapeutic use Carcinoma, Hepatocellular - blood supply Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism Humans Liver Neoplasms - blood supply Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Neovascularization, Pathologic - physiopathology Prognosis Protein Kinase Inhibitors - therapeutic use Sorafenib - therapeutic use Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism
ISSN:	1078-0432, 1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is the second leading cause of cancer-related deaths worldwide. The hypervascular nature of most HCC tumors underlines the importance of angiogenesis in the pathobiology of these tumors. Several angiogenic pathways have been identified as being dysregulated in HCC, suggesting they may be involved in the development and pathogenesis of HCC. These data provide practical targets for systemic treatments such as those targeting the vascular endothelial growth factor receptor and its ligand. However, the clinical relevance of other more recently identified angiogenic pathways in HCC pathogenesis or treatment remains unclear. Research into molecular profiles and validation of prognostic or predictive biomarkers will be required to identify the patient subsets most likely to experience meaningful benefit from this important class of agents.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1078-0432 1557-3265 1557-3265
DOI:	10.1158/1078-0432.CCR-18-1254